OpenURL Connection Search

Select item for more details and to access through your institution.

multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site.
Published in:
Japanese Journal of Clinical Oncology, 2022, v. 52, n. 12, p. 1416, doi. 10.1093/jjco/hyac143
By:
- Nishikawa, Kazuo;
- Hironaka, Shuichi;
- Inagaki, Takashi;
- Komori, Azusa;
- Otsu, Satoshi;
- Mitsugi, Kenji;
- Makiyama, Akitaka;
- Watanabe, Koichiro;
- Tamura, Shingo;
- Okumura, Yuta;
- Kusaba, Hitoshi;
- Esaki, Taito;
- Baba, Eishi;
- Shirao, Kuniaki
Publication type:
Article
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Published in:
Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-34962-7
By:
- Shirakawa, Tsuyoshi;
- Makiyama, Akitaka;
- Shimokawa, Mototsugu;
- Otsuka, Taiga;
- Shinohara, Yudai;
- Koga, Futa;
- Ueda, Yujiro;
- Nakazawa, Junichi;
- Otsu, Satoshi;
- Komori, Azusa;
- Arima, Shiho;
- Fukahori, Masaru;
- Taguchi, Hiroki;
- Honda, Takuya;
- Shibuki, Taro;
- Nio, Kenta;
- Ide, Yasushi;
- Ureshino, Norio;
- Mizuta, Toshihiko;
- Mitsugi, Kenji
Publication type:
Article
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Published in:
International Journal of Clinical Oncology, 2023, v. 28, n. 8, p. 1073, doi. 10.1007/s10147-023-02354-6
By:
- Komori, Azusa;
- Otsu, Satoshi;
- Shimokawa, Mototsugu;
- Otsuka, Taiga;
- Koga, Futa;
- Ueda, Yujiro;
- Nakazawa, Junichi;
- Arima, Shiho;
- Fukahori, Masaru;
- Okabe, Yoshinobu;
- Makiyama, Akitaka;
- Taguchi, Hiroki;
- Honda, Takuya;
- Shibuki, Taro;
- Nio, Kenta;
- Ide, Yasushi;
- Ureshino, Norio;
- Mizuta, Toshihiko;
- Shirakawa, Tsuyoshi;
- Mitsugi, Kenji
Publication type:
Article
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Published in:
International Journal of Clinical Oncology, 2022, v. 27, n. 9, p. 1450, doi. 10.1007/s10147-022-02208-7
By:
- Ito, Takahiko;
- Takashima, Atsuo;
- Yamazaki, Kentaro;
- Yukami, Hiroki;
- Uetake, Hiroyuki;
- Tsuda, Masahiro;
- Suto, Takeshi;
- Moriwaki, Toshikazu;
- Sugimoto, Naotoshi;
- Ojima, Hitoshi;
- Takii, Yasumasa;
- Yasui, Hisateru;
- Esaki, Taito;
- Tsuji, Akihito;
- Goto, Masahiro;
- Saruta, Masayuki;
- Otsu, Satoshi;
- Shinozaki, Katsunori;
- Fujiwara, Toshiyoshi;
- Tamura, Takao
Publication type:
Article
Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Published in:
2021
By:
- Otsuka, Taiga;
- Shirakawa, Tsuyoshi;
- Shimokawa, Mototsugu;
- Koga, Futa;
- Kawaguchi, Yasunori;
- Ueda, Yujiro;
- Nakazawa, Junichi;
- Komori, Azusa;
- Otsu, Satoshi;
- Arima, Shiho;
- Fukahori, Masaru;
- Okabe, Yoshinobu;
- Makiyama, Akitaka;
- Taguchi, Hiroki;
- Honda, Takuya;
- Shibuki, Taro;
- Nio, Kenta;
- Ide, Yasushi;
- Mizuta, Toshihiko;
- Mitsugi, Kenji
Publication type:
Correction Notice
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Published in:
International Journal of Clinical Oncology, 2021, v. 26, n. 5, p. 941, doi. 10.1007/s10147-021-01859-2
By:
- Otsuka, Taiga;
- Shirakawa, Tsuyoshi;
- Shimokawa, Mototsugu;
- Koga, Futa;
- Kawaguchi, Yasunori;
- Ueda, Yujiro;
- Nakazawa, Junichi;
- Komori, Azusa;
- Otsu, Satoshi;
- Arima, Shiho;
- Fukahori, Masaru;
- Okabe, Yoshinobu;
- Makiyama, Akitaka;
- Taguchi, Hiroki;
- Honda, Takuya;
- Shibuki, Taro;
- Nio, Kenta;
- Ide, Yasushi;
- Mizuta, Toshihiko;
- Mitsugi, Kenji
Publication type:
Article
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
Published in:
Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-65689-8
By:
- Shibuki, Taro;
- Otsuka, Taiga;
- Shimokawa, Mototsugu;
- Nakazawa, Junichi;
- Arima, Shiho;
- Fukahori, Masaru;
- Miwa, Keisuke;
- Okabe, Yoshinobu;
- Koga, Futa;
- Ueda, Yujiro;
- Kubotsu, Yoshihito;
- Makiyama, Akitaka;
- Shimokawa, Hozumi;
- Takeshita, Shigeyuki;
- Nishikawa, Kazuo;
- Komori, Azusa;
- Otsu, Satoshi;
- Hosokawa, Ayumu;
- Sakai, Tatsunori;
- Oda, Hisanobu
Publication type:
Article
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
Published in:
Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-63172-y
By:
- Kodama, Tomoko;
- Imajima, Takashi;
- Shimokawa, Mototsugu;
- Otsuka, Taiga;
- Kawahira, Masahiro;
- Nakazawa, Junichi;
- Hori, Takeshi;
- Shibuki, Taro;
- Arima, Shiho;
- Ido, Akio;
- Miwa, Keisuke;
- Okabe, Yoshinobu;
- Koga, Futa;
- Ueda, Yujiro;
- Kubotsu, Yoshihito;
- Shimokawa, Hozumi;
- Takeshita, Shigeyuki;
- Nishikawa, Kazuo;
- Komori, Azusa;
- Otsu, Satoshi
Publication type:
Article
Comparison of Amoxicillin–Metronidazole Plus Famotidine or Lansoprazole for Amoxicillin–Clarithromycin–Proton Pump Inhibitor Treatment Failures for Helicobacter pylori Infection.
Published in:
Helicobacter, 2006, v. 11, n. 5, p. 436, doi. 10.1111/j.1523-5378.2006.00435.x
By:
- Murakami, Kazunari;
- Okimoto, Tadayoshi;
- Kodama, Masaaki;
- Sato, Ryugo;
- Miyajima, Hajime;
- Ono, Masami;
- Inoue, Kunimitsu;
- Watanabe, Koichiro;
- Otsu, Satoshi;
- Fujioka, Toshio
Publication type:
Article
Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer.
Published in:
Cancers, 2023, v. 15, n. 18, p. 4564, doi. 10.3390/cancers15184564
By:
- Otsu, Satoshi;
- Hironaka, Shuichi
Publication type:
Article
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321.
Published in:
Cancer Medicine, 2023, v. 12, n. 14, p. 14988, doi. 10.1002/cam4.6135
By:
- Kasai, Takashi;
- Mori, Kiyoshi;
- Nakamura, Yoichi;
- Seki, Nobuhiko;
- Ichikawa, Yasuko;
- Saito, Haruhiro;
- Kondo, Tetsuro;
- Nishikawa, Kazuo;
- Otsu, Satoshi;
- Bessho, Akihiro;
- Tanaka, Hiroshi;
- Yamaguchi, Hiroyuki;
- Kaburagi, Takayuki;
- Imai, Hisao;
- Mori, Keita;
- Ohtake, Junya;
- Okamoto, Hiroaki
Publication type:
Article
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Published in:
2022
By:
- Shibuki, Taro;
- Mizuta, Toshihiko;
- Shimokawa, Mototsugu;
- Koga, Futa;
- Ueda, Yujiro;
- Nakazawa, Junichi;
- Komori, Azusa;
- Otsu, Satoshi;
- Arima, Shiho;
- Fukahori, Masaru;
- Makiyama, Akitaka;
- Taguchi, Hiroki;
- Honda, Takuya;
- Mitsugi, Kenji;
- Nio, Kenta;
- Ide, Yasushi;
- Ureshino, Norio;
- Shirakawa, Tsuyoshi;
- Otsuka, Taiga
Publication type:
journal article
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Published in:
Gastric Cancer, 2019, v. 22, n. 4, p. 817, doi. 10.1007/s10120-018-0903-1
By:
- Doi, Toshihiko;
- Iwasa, Satoru;
- Muro, Kei;
- Satoh, Taroh;
- Hironaka, Shuichi;
- Esaki, Taito;
- Nishina, Tomohiro;
- Hara, Hiroki;
- Machida, Nozomu;
- Komatsu, Yoshito;
- Shimada, Yasuhiro;
- Otsu, Satoshi;
- Shimizu, Shin;
- Watanabe, Morihiro
Publication type:
Article
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Published in:
Targeted Oncology, 2024, v. 19, n. 2, p. 181, doi. 10.1007/s11523-024-01043-2
By:
- Matsumoto, Toshihiko;
- Yamamoto, Yoshiyuki;
- Kotaka, Masahito;
- Masuishi, Toshiki;
- Tsuji, Yasushi;
- Shoji, Hirokazu;
- Hirata, Kenro;
- Tsuduki, Takao;
- Makiyama, Akitaka;
- Izawa, Naoki;
- Takahashi, Naoki;
- Tsuda, Masahiro;
- Yasui, Hisateru;
- Ohta, Takashi;
- Kito, Yosuke;
- Otsu, Satoshi;
- Hironaka, Shuichi;
- Yamazaki, Kentaro;
- Boku, Narikazu;
- Hyodo, Ichinosuke
Publication type:
Article
Vesicocutaneous fistula formation duringtreatment with sunitinib malate: Case report.
Published in:
2010
By:
- Watanabe, Koichiro;
- Otsu, Satoshi;
- Morinaga, Ryotaro;
- Kawano, Sakura;
- Hirashima, Yoshinori;
- Sakashita, Hiroyuki;
- Shirao, Kuniaki
Publication type:
Case Study
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study.
Published in:
Oncology, 2023, v. 101, n. 1, p. 22, doi. 10.1159/000527176
By:
- Nakazawa, Junichi;
- Tsuruta, Nobuhiro;
- Shimokawa, Mototsugu;
- Kawahira, Machiko;
- Arima, Shiho;
- Ido, Akio;
- Koga, Futa;
- Ueda, Yujiro;
- Komori, Azusa;
- Otsu, Satoshi;
- Fukahori, Masaru;
- Makiyama, Akitaka;
- Taguchi, Hiroki;
- Honda, Takuya;
- Shibuki, Taro;
- Nio, Kenta;
- Ide, Yasushi;
- Ureshino, Norio;
- Mizuta, Toshihiko;
- Otsuka, Taiga
Publication type:
Article
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Published in:
Cancer Science, 2019, v. 110, n. 11, p. 3565, doi. 10.1111/cas.14198
By:
- Hamaguchi, Tetsuya;
- Denda, Tadamichi;
- Kudo, Toshihiro;
- Sugimoto, Naotoshi;
- Ura, Takashi;
- Yamazaki, Kentaro;
- Fujii, Hirofumi;
- Kajiwara, Takeshi;
- Nakajima, Takako Eguchi;
- Takahashi, Shin;
- Otsu, Satoshi;
- Komatsu, Yoshito;
- Nagashima, Fumio;
- Moriwaki, Toshikazu;
- Esaki, Taito;
- Sato, Takeo;
- Itabashi, Michio;
- Oki, Eiji;
- Sasaki, Toru;
- Chiron, Marielle
Publication type:
Article
Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer.
Published in:
Cancer Science, 2019, v. 110, n. 3, p. 1032, doi. 10.1111/cas.13943
By:
- Denda, Tadamichi;
- Sakai, Daisuke;
- Hamaguchi, Tetsuya;
- Sugimoto, Naotoshi;
- Ura, Takashi;
- Yamazaki, Kentaro;
- Fujii, Hirofumi;
- Kajiwara, Takeshi;
- Nakajima, Takako Eguchi;
- Takahashi, Shin;
- Otsu, Satoshi;
- Komatsu, Yoshito;
- Nagashima, Fumio;
- Moriwaki, Toshikazu;
- Esaki, Taito;
- Sato, Takeo;
- Itabashi, Michio;
- Oki, Eiji;
- Sasaki, Toru;
- Sunaga, Yoshinori
Publication type:
Article
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Published in:
2024
By:
- Shirakawa, Tsuyoshi;
- Makiyama, Akitaka;
- Shimokawa, Mototsugu;
- Otsuka, Taiga;
- Shinohara, Yudai;
- Koga, Futa;
- Ueda, Yujiro;
- Nakazawa, Junichi;
- Otsu, Satoshi;
- Komori, Azusa;
- Arima, Shiho;
- Fukahori, Masaru;
- Taguchi, Hiroki;
- Honda, Takuya;
- Shibuki, Taro;
- Nio, Kenta;
- Ide, Yasushi;
- Ureshino, Norio;
- Mizuta, Toshihiko;
- Mitsugi, Kenji
Publication type:
Correction Notice
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
Published in:
Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-46924-0
By:
- Fukahori, Masaru;
- Okabe, Yoshinobu;
- Shimokawa, Mototsugu;
- Otsuka, Taiga;
- Koga, Futa;
- Ueda, Yujiro;
- Nakazawa, Junichi;
- Komori, Azusa;
- Otsu, Satoshi;
- Arima, Shiho;
- Makiyama, Akitaka;
- Taguchi, Hiroki;
- Honda, Takuya;
- Ushijima, Tomoyuki;
- Miwa, Keisuke;
- Shibuki, Taro;
- Nio, Kenta;
- Ide, Yasushi;
- Ureshino, Norio;
- Mizuta, Toshihiko
Publication type:
Article

Found: 20